[ Synpromics raises $6.59M in Venture ]

Synpromics has raised $6.59 million in Venture.

Founded in 2010, Synpromics focuses on commercializing proprietary technology that gives biological researchers, developers and manufacturers control of gene expression through the ability to create a comprehensive portfolio of man-made DNA regulatory sequences.

The company intends to use the funds to further develop and exemplify Synpromics proprietary PromPT™ synthetic promoter design platform.

Funding  Venture
Founded  2010
Country  UK
City  Edinburgh, Edinburgh, City of
Founder / CEO  David C. Venables
Deal Size  $6.59M
Investors  Calculus Capital
 Scottish Investment Bank
Previous Investors  Calculus Capital

[adyen action=”checkout_button”]